Research compound comparison · research use
Retatrutide vs tirzepatide: dual agonist vs triple agonist.
Retatrutide and tirzepatide are both incretin receptor-agonist peptides, so they get cross-searched — but they aren't the same compound. Tirzepatide is studied as a dual GIP/GLP-1 receptor agonist; retatrutide is studied as a triple GIP/GLP-1/glucagon receptor agonist, adding a third receptor arm. That one mechanistic difference is the whole comparison. This page lays out what each is, the receptor pathways each engages in research, available formats, and the documentation standard behind both.
| Attribute | Retatrutide | Tirzepatide |
|---|---|---|
| Class | Triple incretin receptor agonist (peptide) | Dual incretin receptor agonist (peptide) |
| Receptor pathways studied | GIP, GLP-1, and glucagon receptor signaling | GIP and GLP-1 receptor signaling |
| Mechanistic distinction | Adds a third receptor arm (glucagon) on top of the dual-agonist framework studied in metabolic-research models | Dual-incretin framework — the two-receptor baseline that the triple agonist is most often contrasted against |
| Why they're compared | Both appear in incretin / metabolic receptor-agonist research and are cross-searched as the dual-vs-triple question | Same — they are the canonical 'two receptors vs three receptors' pairing in this research area |
| Titan format | Retatrutide research vial, lyophilized for reconstitution | Sourced as a research compound; see the tirzepatide buyer page for current format |
| Documentation | Lot-matched release sheet, HPLC purity target with identity confirmation | Lot-matched release sheet, HPLC purity target with identity confirmation |
Dual agonist vs triple agonist
The single distinction researchers care about: tirzepatide is studied as a dual GIP/GLP-1 receptor agonist, while retatrutide adds a third arm — glucagon-receptor signaling — making it a triple GIP/GLP-1/glucagon agonist. That extra receptor pathway is the entire reason the two are cross-searched. Both are handled by Titan strictly as research compounds, never as substitutes for one another or for any approved medication.
View retatrutide →Retatrutide is the triple-agonist peptide
If your study design is built around three-receptor incretin signaling — GIP, GLP-1, and glucagon together — retatrutide, not tirzepatide, is the relevant compound. Titan supplies retatrutide as a lyophilized research vial with lot documentation referenced to the lot code on the unit, so the material in front of you matches the paperwork.
Where to buy retatrutide →Same documentation standard for both
Whichever receptor framework you're studying, the paper-trail standard does not change: a lot-matched in-house release sheet referenced to the lot code on the unit, against an HPLC purity target with identity confirmation. That consistency is what separates a documented supplier from a blind one — and it is the only claim Titan makes about these compounds.
How to verify a COA →Choose by the receptor framework you're studying
Pick by the number of receptor arms your research model targets: two (GIP/GLP-1) points to tirzepatide, three (GIP/GLP-1/glucagon) points to retatrutide. They are not interchangeable. Avoid any supplier that attaches weight-loss, dosing, or human-use claims to either — that marketing language is a compliance red flag, not science. For all three side by side, see the full GLP-1 comparison.
Add semaglutide to the comparison →See the product pages.
Open the retatrutide research vial for size, lot documentation, and crypto checkout, check the tirzepatide buyer page, or browse the full research catalog.
Compare research compounds
Other peptide comparisons researchers run before sourcing.
Each Titan comparison breaks down the structural differences, research format, and documentation a buyer should confirm — lot-matched COA, HPLC purity target, and a clear research-use boundary. Pick the pair you're evaluating.
GLP-1 / metabolic research
Growth-hormone secretagogue research
Recovery & repair research
Neuropeptide & nasal-format research